Of high translational relevance, silencing of GPT2 in the β-cells of human T2D islets restored glucose and Ex4 responsiveness, raising GPT2 as a therapeutic target to mitigate β-cell dysfunction in diabetes. The gene discussed is GPT2; the disease is type 2 diabetes mellitus.